350
Participants
Start Date
February 13, 2024
Primary Completion Date
January 8, 2029
Study Completion Date
January 8, 2029
Tocilizumab
"The initial dose of tocilizumab will be administered in the operating room before reperfusion of the first lung during the lung transplant surgery.~6 doses will be given once every four weeks over a 20-week period. The dose is approved for pediatric patients who weigh 30 kg or more"
Placebo for Tocilizumab
"Placebo 0.9% Sodium Chloride Injection USP (Normal Saline)~Placebo will be given as a single intravenous dose, volume matched to tocilizumab. Placebo will be administered over a period of approximately 60 minutes; once every four weeks over a 20-week period. The first placebo dose will be during the transplant surgery before reperfusion of the first lung allograft, with 5 subsequent monthly doses"
RECRUITING
Columbia University Medical Center (Site #: 71113), New York
WITHDRAWN
University of Maryland Medical Center (Site #: 71138), Baltimore
RECRUITING
Duke University Medical Center (Site #: 71139), Durham
RECRUITING
Cleveland Clinic (Site #: 71101), Cleveland
RECRUITING
Barnes Jewish Hospital/ Washington University SOM (Site #: 71191), St Louis
WITHDRAWN
St. Louis Children's Hospital of Washington University (Site #: 71006), St Louis
RECRUITING
University of Texas Southwestern (Site #: 71187), Dallas
WITHDRAWN
Houston Methodist Hospital (Site #: 71120), Houston
RECRUITING
University of Utah Medical Center (Site #: 71126), Salt Lake City
RECRUITING
St. Joseph's Hospital and Medical Center (Site #: 71192), Phoenix
RECRUITING
Cedars Sinai Medical Center (Site #: 71146), Los Angeles
RECRUITING
David Geffen School of Medicine at UCLA (Site #: 71123), Los Angeles
RECRUITING
Massachusetts General Hospital (Site #: 71107), Boston
WITHDRAWN
Boston Children's Hospital and Harvard Medical School (Site #: 71001), Boston
National Institute of Allergy and Infectious Diseases (NIAID)
NIH